Literature DB >> 32006497

Incentivising antibiotic research and development: is the UK's subscription payment model part of the solution?

Michael Anderson1, Elias Mossialos2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32006497     DOI： 10.1016/S1473-3099(19)30701-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  1 in total

1.  Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study.

Authors:  Nadine T Hillock; Tracy L Merlin; Jonathan Karnon; John Turnidge; Jaklin Eliott
Journal:  JAC Antimicrob Resist       Date:  2020-05-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.